PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 24, 2014Clinical Cancer Research809 citationsOpen Access

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

View Full Paper
PRPaul F. RobbinsSKSadik H. KassimTTThai L.N. Tran

Key Points

Key points are not available for this paper at this time.

Abstract

The adoptive transfer of autologous T cells transduced with a retrovirus encoding a TCR against an HLA-A*0201 restricted NY-ESO-1 epitope can be an effective therapy for some patients bearing synovial cell sarcomas and melanomas that are refractory to other treatments.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Robbins et al. (2014) studied this question.

synapsesocial.com/papers/69d9cfbd0f32475823a3c667https://doi.org/10.1158/1078-0432.ccr-14-2708
Ask AI
Helpful
Bookmark
Share
View Full Paper